Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Biodexa Pharmaceuticals PLC
BDRX
Healthcare
Biotechnology
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing...
technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:BDRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
•••
Jonathon Brown
X
Post by
Jonathon Brown
on Nov 28, 2024 5:55am
Buzz on the Bullboards: Stocks to watch in volatile times.
The TSX hit another record high on strong retail sales data and positive investor sentiment. However, the index quickly fell from grace.
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 27, 2024 12:15pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 26, 2024 8:15pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
(271)
•••
whytestocks
X
Post by
whytestocks
on Nov 22, 2024 1:15pm
Result of General Meeting
BREAKING NEWS: $BDRX Result of General MeetingNovember 22, 2024 Biodexa Pharmaceuticals PLC (“ Biodexa ” or the “ Company ”) Result of General Meeting
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 22, 2024 11:04am
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK CITY, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 22, 2024 8:30am
New Press Release - Result of General Meeting
November 22, 2024Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Result of General MeetingBiodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 21, 2024 7:37am
New Press Release - Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 20, 2024 8:00pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 18, 2024 9:13pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ: BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 16, 2024 12:03pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2024 6:46pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 12, 2024 8:32pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 12, 2024 8:48am
New Press Release - Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Regains Compliance For Continued Listing on Nasdaq
November 12, 2024Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on NasdaqBiodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with...
read article.
(271)
•••
whytestocks
X
Post by
whytestocks
on Nov 07, 2024 11:45pm
Notice of General Meeting
News; $BDRX Notice of General MeetingNovember 7, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 07, 2024 4:30pm
New Press Release - Notice of General Meeting
November 7, 2024Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)Notice of General MeetingBiodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 04, 2024 3:46pm
New Press Release - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The...
read article.
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth